BioCentury | May 29, 2020
Distillery Therapeutics

Inhibitors of an orphan nuclear receptor for prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Small molecule inhibitors of NR2F2, an orphan nuclear receptor, could treat prostate cancer. High throughput screening of >370,000 compounds for NR2F2 inhibitors yielded two dimethoxybenzene-based molecules that blocked the...
BioCentury | Sep 30, 2019
Company News

Sept. 30 Company Quick Takes: Lumos-NewLink, Simcere-JW, Ocugen-CanSino, Chamishi’s launch, and AbbVie-Allergan

Lumos finds public pat h Rare disease company Lumos Pharma Inc. plans to go public via a reverse merger with NewLink Genetics Corp. (NASDAQ:NLNK). Set to own about 50% of the combined company are Lumos’...
BioCentury | May 20, 2019
Distillery Therapeutics

Treating obesity and metabolic syndrome via NR4A2 agonism

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; metabolic syndrome Mouse studies suggest agonizing NR4A2 could help treat obesity and obesity-associated metabolic syndrome. In a mouse model of diet-induced obesity, skeletal muscle-specific NR4A2 overexpression increased glucose tolerance and...
BioCentury | Mar 7, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

New Therapeutic Targets and Biomarkers: February 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Mar 5, 2019
Distillery Therapeutics

Inhibiting NR4A1, NR4A2 and N4RA3 in CAR Ts to enhance efficacy in solid tumors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Mouse studies suggest inhibiting NR4A1, NR4A2 and NR4A3 in CAR T cells could enhance the cells' efficacy in melanoma, colorectal cancer and other solid tumor types. In CD8+...
BioCentury | Feb 28, 2019
Preclinical News

Removing genes from CAR Ts to improve efficacy, safety

Two studies have identified genes that could be knocked out from CAR T cells to improve efficacy or safety. While CAR T cells are effective against B cell malignancies, their efficacy in solid tumors has...
BioCentury | Jan 8, 2019
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) In vitro and mouse studies identified an NR1D1 agonist that could help treat MS. Optimization and in vitro binding assays of analogs of a previously reported benzohydrazide-based NR1D1 agonist yielded a...
BioCentury | Oct 25, 2018
Distillery Techniques

Biomarkers

...larger cohorts of breast cancer patients. DESCRIPTION: Percentage of bone marrow-disseminated tumor cells with high nuclear receptor subfamily 2 group F member 1...
...Oslo University Hospital, Oslo, Norway email: BNA@ous-hf.no Sandi Wong Icahn School of Medicine at Mount Sinai Oslo University Hospital Nuclear receptor subfamily 2 group F member 1...
BioCentury | Jul 18, 2018
Translation in Brief

Playing chicken with metastasis

...identified 11 hits, including kinesin family member 3B (KIF3B), SRSF protein kinase 1 (SRPK1) and nuclear receptor subfamily 2 group F member 1...
...Staff Writer EFX001 Entos Pharmaceuticals Inc. University of Alberta CD151 molecule (Raph blood group) (CD151) (TSPAN24) Kinesin family member 3b (KIF3B) Nuclear receptor subfamily 2 group F member 1...
BioCentury | Jul 18, 2018
Distillery Techniques

Assays and screens

...KIF3B), actin β (ACTB) and SRSF protein kinase 1 (SRPK1) as the top-ranked hits and nuclear receptor subfamily 2 group F member 1...
...Edmonton, Alberta email: jdlewis@ualberta.ca Jaime De Leon Entos Pharmaceuticals Inc. University of Alberta Actin beta (ACTB) Kinesin family member 3A (KIF3A) Nuclear receptor subfamily 2 group F member 1...
Items per page:
1 - 10 of 49